Search results for " biosimilarity"

Article N-Glycan Analysis of Biotherapeutic Proteins
This article summarizes the approaches, challenges, and future perspectives for the characterization of N-glycans in biopharmaceutical products. By Aled Jones Protein glycosylation, the addi…

Article Drug Quality Key to Innovation and Access
FDA plans to advance initiatives for ensuring reliable production of drugs and biologics in 2017. By Jill Wechsler Amidst multiple challenges to the structure and governance of the US health…

Article A Second Modular Biopharma Facility Opens: KUBio in Hangzhou
To bring advanced biosimilar products to the Chinese market quickly, Pfizer’s Global Biotechnology Center will make use of Cytiva’s KUBio advanced modular manufacturing solution. KUBio modules …

Article Applications of Surface Plasmon Resonance for Detection of Bispecific Antibody Activity
FDA, Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product (Rockville, MD, Apr. 2015). 19. C. Gassner et al., J. Pharm Biomed Anal. 102…

Article Drugs, At What Cost?
Generics, market dynamics, and global demand are changing drug spending patterns. The underlying question for any drug in development is: What price can (or will) patients pay for the needed…

Article Milestones and Moderate Progress in 2012 Drug Approvals
First gene therapy and plant-based expression vector products approved in 2012. In terms of product approvals, the past year can be considered reasonably successful. Twelve biopharm…

Article A Look into Biologic Scale-Up Strategies
Optimizing cell-culture processes for monoclonal antibody (mAb) production is a key factor in scaling up manufacturing to commercial levels. To maximize cell-culture output, strategy is requir…

Article Optimizing your Cell Culture Process to Improve Productivity
Cell Culture Process In this video, Mary Szorik and Alicia Elwood at Cytiva, discuss the rationale for cell culture and analytical testing as well as the types of tests that can lead …

Article Pandemic Alters Policies and Practices for Drug Development and Regulation
By Jill Wechsler The need for medicines to combat COVID-19 has impacted the way regulatory agencies carry out their operations. Drug development and regulati…

Article Maximum Output Starts with Optimized Upstream Processing
By Cynthia A. Challener Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity. Significant growth in the develo…

Previous PageNext Page